C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer

British Journal of Cancer

Volumn 102, Issue 2, 2010, Pages 325-331

  Yamaguchi, K ^a,b   Sakai, M ^a,b   Shimokawa, T ^a   Yamada, Y ^a   Nakamura, Y ^a   Furukawa, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

BRD8; C20orf20 (MRGBP); Cell proliferation; Colorectal cancer

Indexed keywords

BINDING PROTEIN; PROTEIN C20ORF20; PROTEIN SUBUNIT; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA INTERFERENCE; UPREGULATION;

CARRIER PROTEINS; CELL LINE, TUMOR; CELLS, CULTURED; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, THYROID HORMONE;

EID: 75549089033     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605500     Document Type: Article

References (16)

1. Cai Y, Jin J, Tomomori-Sato C, Sato S, Sorokina I, Parmely TJ, Conaway RC, Conaway JW (2003) Identification of new subunits of the multiprotein mammalian TRRAP/TIP60-containing histone acetyltransferase complex. J Biol Chem 278: 42733-42736
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246
3. Giantonio BJ (2006) Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second-and third-line settings. Semin Oncol 33: S15-S18
4. Gridelli C, Rossi A, Maione P (2003) Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 22: 6629-6638
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
6. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158 (Pubitemid 37432975)
7. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y (2002) Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21: 4120-4128
8. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749
9. Monden T, Kishi M, Hosoya T, Satoh T, Wondisford FE, Hollenberg AN, Yamada M, Mori M (1999) p120 acts as a specific coactivator for 9-cis-retinoic acid receptor (RXR) on peroxisome proliferator-activated receptor-gamma/RXR heterodimers. Mol Endocrinol 13: 1695-1703
10. Monden T, Wondisford FE, Hollenberg AN (1997) Isolation and characterization of a novel ligand-dependent thyroid hormone recep-tor-coactivating protein. J Biol Chem 272: 29834-29841
11. Nielsen MS, Petersen CM, Gliemann J, Madsen P (1996) Cloning and sequencing of a human cDNA encoding a putative transcription factor containing a bromodomain. Biochim Biophys Acta 1306: 14-16 (Pubitemid 26122254)
12. O'Dwyer ME, Druker BJ (2000) Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 12: 594-597
13. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543
14. Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM, Nakamura Y (2003) Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res 63: 6116-6120
15. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T, Van Laethem JL, Soulie P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25: 5225-5232
16. Wakeling AE (2002) Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol 2: 382-387